National Center for Advancing Translational Sciences – Cures Acceleration Network

NCATS - CAN
CFDA 93.TR3 Active Grant Cooperative Agreement

Program Funding

Annual program obligations reported to SAM.gov.

Latest annual funding (estimated)
$16M FY2026
$16M
FY26*
* estimated

Program Objective

The National Center for Advancing Translational Sciences' (NCATS') mission is to turn research observations into health solutions through translational science. We work to develop or enhance the development, testing, and implementation of diagnostics and therapeutics for a wide range of diseases and conditions. Key approaches include understanding what’s similar across diseases to spur multiple treatments at a time, developing models that better predict a person’s reaction to treatment, enhancing clinical trials so results more accurately reflect the patient population, and leveraging real-world data and data science approaches to address public health needs. Facilitating these approaches are our robust partnerships with other government agencies, including other NIH institutes, centers, and offices; industry; academia; nonprofit organizations; and patients, patient advocates, and other communities. NCATS' vision is to bring more treatments for all people more quickly.

Eligibility

Eligible Applicants

  • U.S. Federal Government
  • U.S. State Government
  • U.S. Territory Government
  • Department/Agency of U.S. State
  • Department/Agency of U.S. Territorial Gov
  • Interstate Organization
  • Federally Recognized Tribal Government
  • Tribal Government (other)
  • Tribally Designated Housing Authority
  • Municipality/Township Government
  • County Government
  • School District Government
  • School District
  • Local Government Consortium
  • Public Housing Authority
  • Other Special District Government
  • Local
  • State
  • Territorial
  • Tribal
  • Foreign Nonprofit Organization
  • Foreign Not-for-Profit Organization
  • Foreign For-Profit Organization
  • International Organization
  • Nonprofit Organization
  • Not-for-Profit Organization
  • For-Profit Organization

How to Apply

Award Procedure

The initial review of applications from eligible institutions is conducted by committees comprised of authorities in various fields of biomedical research and science education, as appropriate. Each application is given a peer evaluation for merit. Recommendations for award are forwarded to the NCATS Advisory Council for the second level of review and recommendation for award.

Decision Timeline

  • Approval: > 180 Days
  • Renewal interval: > 180 Days
  • Appeal: From 15 to 30 days
Program details & compliance

Description

The functions of the Cures Acceleration Network (CAN) are to (1) conduct and support revolutionary advances in basic research, translating scientific discoveries from bench to bedside; (2) award grants and contracts to eligible entities to accelerate the development of high need cures; (3) provide the resources necessary for government agencies, independent investigators, research organizations, biotechnology companies, academic research institutions, and other entities to develop high need cures; (4) reduce the barriers between laboratory discoveries and clinical trials for new therapies; and (5) facilitate review in the Food and Drug Administration for the high need cures funded by the CAN.

Mission Categories

Primary: Research and Development

Other categories:
General Health and Medical

Use of Funds

Allowed Uses

NCATS is all about getting more treatments to all patients more quickly. A novel drug, device or intervention can take 14 years and $2 billion to develop, with a failure rate exceeding 95%. NCATS is directly addressing this problem by discovering new technologies and other approaches that could greatly accelerate the process of developing and deploying solutions that can be used by all translational researchers. NCATS supports expansion of the target landscape for therapeutic development by supporting pilot studies on druggable proteins that have largely been neglected by the research community, but are associated with rare diseases. It also supports strategies that will enable targeting biologic entities that cannot be modulated with traditional drug development of biologic strategies. In cases where a potential therapeutic has been identified for a rare disease, and a model system for testing the treatment has already been established, NCATS will support proof of concept studies to advance development of the candidate treatment. NCATS also supports early-stage development projects for generalizable translational science technologies. Through Translator, NCATS will integrate existing biomedical data to help reveal new relationships within those data and also identify novel opportunities for research. The Tissue Chip program funds bioengineered devices to improve the process of predicting whether drugs will be safe or toxic in humans. The bioprinting program will generate high throughput screenable assay models of human tissues for drug discovery. Quantum Biomedical Innovations and Technologies (Qu-BIT) Program aims to generate innovative quantum-enabled sensing technologies and quantum computing approaches to provide novel capabilities in early disease detection, improving diagnostic approaches, and therapeutic strategies. The NCATS ASPIRE Program develops technology platform for improving drug discovery and pre-clinical testing of new and safer treatments.

Required Documentation

The required credentials of the applicant are described in the relevant Notice of Funding Opportunity.

Reporting & Compliance

Audit Required
Yes — Annual
Records Retention
3 years

Applicable 2 CFR 200 Subparts

  • Subpart B — General Provisions
  • Subpart C — Pre-Federal Award Requirements
  • Subpart D — Post-Federal Award Requirements
  • Subpart E — Cost Principles
  • Subpart F — Audit Requirements

Contacts

NCATSExtramuralInfo
301-594-8966
9609 Medical Center Drive, Rockville, MD 20850
Data from SAM.gov Federal Assistance Listings. Source published: 2026-02-02. Spec v2.0. Last synced: 2026-05-29 05:38:03.